Physician profile
Arsalan Sheikh
NPI 1518971266
$1,616.19
in general payments reported to CMS, 2019-2025
26 companies · $51.99 in 2025
The $51.99 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $62.50 · 2020: $29.99 · 2021: $180 · 2022: $99.94 · 2023: $979 · 2024: $213 · 2025: $51.99.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,202 · Education: $42.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,201.64 |
| Education | $42.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $374.33 | 2021-2024 | |
| Dexcom, INC. | $189.48 | 2021-2023 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $169.40 | 2022-2024 | Ozempic, Rybelsus |
| Xeris Pharmaceuticals, INC. | $130.92 | 2023-2024 | Recorlev, Gvoke Hypopen |
| Lilly USA, LLC | $74.41 | 2023 | Jardiance, Mounjaro |
| Amgen INC. | $64.90 | 2023-2024 | Evenity, Prolia, Tepezza |
| Alexion Pharmaceuticals, INC. | $58.99 | 2023-2024 | Strensiq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.38 | 2022-2023 | Jardiance |
| Medtronic, INC. | $48.21 | 2023-2025 | Minimed 780g, Minimed 770g |
| Cequr Corporation | $42.43 | 2023-2024 | Cequr Simplicity |
| Pfizer INC. | $41.70 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $41.69 | 2022-2023 | |
| Vifor Pharma, INC. | $38.05 | 2019 | |
| Tandem Diabetes Care, INC. | $34.18 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Octapharma USA, INC. | $29.99 | 2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $28.84 | 2021-2023 | |
| Embecta Corp. | $26.94 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Biomarin Pharmaceutical INC. | $25.00 | 2022 | |
| Kerecis Limited | $24.45 | 2019 | |
| Ascensia Diabetes Care US INC. | $23.60 | 2023 | |
| Amryt Pharma Holdings LTD | $19.71 | 2023 | Mycapssa |
| Recordati_rare_diseases_inc. | $18.80 | 2023 | Isturisa, Signifor Lar |
| Insulet Corporation | $18.46 | 2025 | Omnipod |
| Kyowa Kirin, INC. | $16.11 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $13.65 | 2021 | |
| Chiesi USA, INC. | $13.57 | 2024 | Myalept |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arsalan Sheikh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.